744257-63-4

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-fluoro-4-iodo-pyridin-3-yl)-ethanol is used as an intermediate for the synthesis of various pharmaceutical compounds due to its unique structure and functional groups. Its fluorine and iodine substitutions, along with the ethanol group, provide a versatile platform for the development of new drugs and medications.
Used in Drug Development:
In the field of drug development, 1-(2-fluoro-4-iodo-pyridin-3-yl)-ethanol is used as a key component in the creation of novel therapeutic agents. Its unique structure allows for the design of molecules with specific biological activities, potentially leading to the discovery of new treatments for various diseases and conditions.
It is important to handle 1-(2-fluoro-4-iodo-pyridin-3-yl)-ethanol with care and adhere to proper safety protocols when working with it in a laboratory or industrial setting, as it is a chemical compound that may have specific hazards associated with its use.

Upstream product

• 372-48-5 2-fluoropyridine 
• 113975-22-7 2-fluoro-3-iodopyridine 
• 75-07-0 acetaldehyde 

Downstream Products

• 1160502-26-0 4-iodo-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1160500-81-1 2-methyl-2-(3-(3-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)butan-1-amine 

Relevant academic research and scientific papers

Discovery of selective, orally bioavailable pyrazolopyridine inhibitors of protein kinase cθ (pkcθ) that ameliorate symptoms of experimental autoimmune encephalomyelitis

PKCθ plays an important role in T cell biology and is a validated target for a number of disease states. A series of potent and selective PKCθ inhibitors were designed and synthesized starting from a HTS hit compound. Cell activity, while initially a challenge to achieve, was built into the series by transforming the nitrile unit of the scaffold into a primary amine, the latter predicted to form a new hydrogen bond to Asp508 near the entrance of the ATP binding site of PKCθ. Significant improvements in physiochemical parameters were observed on introduction of an oxetane group proximal to a primary amine leading to compound 22, which demonstrated a reduction of symptoms in a mouse model of multiple sclerosis.

[1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA

The present invention relates to compounds of formula (I) and (IA) useful as inhibitors of protein kinase (1a). The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. (a) : in particular protein kinase C theta, wherein A and A' are independently -N- or -C(R+) -. Ring B is five- or six-membered saturated carbocyclic or heterocyclic R1, R2, R3, R4, R5, R6, R7, x and y are as described herein.

A synthetic approach to 2,3,4-substituted pyridines useful as scaffolds for tripeptidomimetics

The synthesis of 2,3,4-substituted pyridine derivatives useful as scaffolds in the development of peptidomimetics is described. The use of a variety of electrophiles in a halogen-dance reaction to produce 3-alkyl-2-fluoro-4-iodo- pyridine derivatives as 'functionalized scaffolds' and the possibility to differentiate between the reactivities of the two halogen handles have been explored. Coupling of amino acid derivatives in the 4-position of the pyridine was found to proceed efficiently by conversion of iodo-pyridine to a Grignard derivative, which was allowed to react with a protected amino aldehyde. Substitution of fluorine in the 2-position of the pyridine was found to be facile with alkoxide nucleophiles, whereas amines were much less reactive.